Global Primary Myelofibrosis Drug Supply, Demand and Key Producers, 2023-2029
The global Primary Myelofibrosis Drug market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).
Primary myelofibrosis (MF) is a chronic blood cancer in which excessive scar tissue forms in the bone marrow and impairs its ability to produce normal blood cells. Researchers believe MF may be caused by abnormal blood stem cells in the bone marrow. The abnormal stem cells produce mature cells that grow quickly and take over the bone marrow, causing both fibrosis (scar tissue formation) and chronic inflammation.
This report studies the global Primary Myelofibrosis Drug production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Primary Myelofibrosis Drug, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Primary Myelofibrosis Drug that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Primary Myelofibrosis Drug total production and demand, 2018-2029, (K Units)
Global Primary Myelofibrosis Drug total production value, 2018-2029, (USD Million)
Global Primary Myelofibrosis Drug production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Primary Myelofibrosis Drug consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Primary Myelofibrosis Drug domestic production, consumption, key domestic manufacturers and share
Global Primary Myelofibrosis Drug production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Primary Myelofibrosis Drug production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Primary Myelofibrosis Drug production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units)
This reports profiles key players in the global Primary Myelofibrosis Drug market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GSK, AbbVie, Novartis, Celgene, Grunenthal, Incyte, CTI BioPharma, Bristol Myers Squibb and Suzhou Zelgen Biopharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Primary Myelofibrosis Drug market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Primary Myelofibrosis Drug Market, By Region:
1. How big is the global Primary Myelofibrosis Drug market?
2. What is the demand of the global Primary Myelofibrosis Drug market?
3. What is the year over year growth of the global Primary Myelofibrosis Drug market?
4. What is the production and production value of the global Primary Myelofibrosis Drug market?
5. Who are the key producers in the global Primary Myelofibrosis Drug market?
6. What are the growth factors driving the market demand?
Primary myelofibrosis (MF) is a chronic blood cancer in which excessive scar tissue forms in the bone marrow and impairs its ability to produce normal blood cells. Researchers believe MF may be caused by abnormal blood stem cells in the bone marrow. The abnormal stem cells produce mature cells that grow quickly and take over the bone marrow, causing both fibrosis (scar tissue formation) and chronic inflammation.
This report studies the global Primary Myelofibrosis Drug production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Primary Myelofibrosis Drug, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Primary Myelofibrosis Drug that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Primary Myelofibrosis Drug total production and demand, 2018-2029, (K Units)
Global Primary Myelofibrosis Drug total production value, 2018-2029, (USD Million)
Global Primary Myelofibrosis Drug production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Primary Myelofibrosis Drug consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Primary Myelofibrosis Drug domestic production, consumption, key domestic manufacturers and share
Global Primary Myelofibrosis Drug production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Primary Myelofibrosis Drug production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Primary Myelofibrosis Drug production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units)
This reports profiles key players in the global Primary Myelofibrosis Drug market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GSK, AbbVie, Novartis, Celgene, Grunenthal, Incyte, CTI BioPharma, Bristol Myers Squibb and Suzhou Zelgen Biopharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Primary Myelofibrosis Drug market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Primary Myelofibrosis Drug Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- JAK 1
- JAK 2
- Others
- Adults
- Children
- GSK
- AbbVie
- Novartis
- Celgene
- Grunenthal
- Incyte
- CTI BioPharma
- Bristol Myers Squibb
- Suzhou Zelgen Biopharmaceuticals
1. How big is the global Primary Myelofibrosis Drug market?
2. What is the demand of the global Primary Myelofibrosis Drug market?
3. What is the year over year growth of the global Primary Myelofibrosis Drug market?
4. What is the production and production value of the global Primary Myelofibrosis Drug market?
5. Who are the key producers in the global Primary Myelofibrosis Drug market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Primary Myelofibrosis Drug Introduction
1.2 World Primary Myelofibrosis Drug Supply & Forecast
1.2.1 World Primary Myelofibrosis Drug Production Value (2018 & 2022 & 2029)
1.2.2 World Primary Myelofibrosis Drug Production (2018-2029)
1.2.3 World Primary Myelofibrosis Drug Pricing Trends (2018-2029)
1.3 World Primary Myelofibrosis Drug Production by Region (Based on Production Site)
1.3.1 World Primary Myelofibrosis Drug Production Value by Region (2018-2029)
1.3.2 World Primary Myelofibrosis Drug Production by Region (2018-2029)
1.3.3 World Primary Myelofibrosis Drug Average Price by Region (2018-2029)
1.3.4 North America Primary Myelofibrosis Drug Production (2018-2029)
1.3.5 Europe Primary Myelofibrosis Drug Production (2018-2029)
1.3.6 China Primary Myelofibrosis Drug Production (2018-2029)
1.3.7 Japan Primary Myelofibrosis Drug Production (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Primary Myelofibrosis Drug Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Primary Myelofibrosis Drug Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Primary Myelofibrosis Drug Demand (2018-2029)
2.2 World Primary Myelofibrosis Drug Consumption by Region
2.2.1 World Primary Myelofibrosis Drug Consumption by Region (2018-2023)
2.2.2 World Primary Myelofibrosis Drug Consumption Forecast by Region (2024-2029)
2.3 United States Primary Myelofibrosis Drug Consumption (2018-2029)
2.4 China Primary Myelofibrosis Drug Consumption (2018-2029)
2.5 Europe Primary Myelofibrosis Drug Consumption (2018-2029)
2.6 Japan Primary Myelofibrosis Drug Consumption (2018-2029)
2.7 South Korea Primary Myelofibrosis Drug Consumption (2018-2029)
2.8 ASEAN Primary Myelofibrosis Drug Consumption (2018-2029)
2.9 India Primary Myelofibrosis Drug Consumption (2018-2029)
3 WORLD PRIMARY MYELOFIBROSIS DRUG MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Primary Myelofibrosis Drug Production Value by Manufacturer (2018-2023)
3.2 World Primary Myelofibrosis Drug Production by Manufacturer (2018-2023)
3.3 World Primary Myelofibrosis Drug Average Price by Manufacturer (2018-2023)
3.4 Primary Myelofibrosis Drug Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Primary Myelofibrosis Drug Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Primary Myelofibrosis Drug in 2022
3.5.3 Global Concentration Ratios (CR8) for Primary Myelofibrosis Drug in 2022
3.6 Primary Myelofibrosis Drug Market: Overall Company Footprint Analysis
3.6.1 Primary Myelofibrosis Drug Market: Region Footprint
3.6.2 Primary Myelofibrosis Drug Market: Company Product Type Footprint
3.6.3 Primary Myelofibrosis Drug Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Primary Myelofibrosis Drug Production Value Comparison
4.1.1 United States VS China: Primary Myelofibrosis Drug Production Value Comparison (2018 & 2022 & 2029)
4.1.2 United States VS China: Primary Myelofibrosis Drug Production Value Market Share Comparison (2018 & 2022 & 2029)
4.2 United States VS China: Primary Myelofibrosis Drug Production Comparison
4.2.1 United States VS China: Primary Myelofibrosis Drug Production Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Primary Myelofibrosis Drug Production Market Share Comparison (2018 & 2022 & 2029)
4.3 United States VS China: Primary Myelofibrosis Drug Consumption Comparison
4.3.1 United States VS China: Primary Myelofibrosis Drug Consumption Comparison (2018 & 2022 & 2029)
4.3.2 United States VS China: Primary Myelofibrosis Drug Consumption Market Share Comparison (2018 & 2022 & 2029)
4.4 United States Based Primary Myelofibrosis Drug Manufacturers and Market Share, 2018-2023
4.4.1 United States Based Primary Myelofibrosis Drug Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Primary Myelofibrosis Drug Production Value (2018-2023)
4.4.3 United States Based Manufacturers Primary Myelofibrosis Drug Production (2018-2023)
4.5 China Based Primary Myelofibrosis Drug Manufacturers and Market Share
4.5.1 China Based Primary Myelofibrosis Drug Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Primary Myelofibrosis Drug Production Value (2018-2023)
4.5.3 China Based Manufacturers Primary Myelofibrosis Drug Production (2018-2023)
4.6 Rest of World Based Primary Myelofibrosis Drug Manufacturers and Market Share, 2018-2023
4.6.1 Rest of World Based Primary Myelofibrosis Drug Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Primary Myelofibrosis Drug Production Value (2018-2023)
4.6.3 Rest of World Based Manufacturers Primary Myelofibrosis Drug Production (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Primary Myelofibrosis Drug Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 JAK
5.2.2 JAK
5.2.3 Others
5.3 Market Segment by Type
5.3.1 World Primary Myelofibrosis Drug Production by Type (2018-2029)
5.3.2 World Primary Myelofibrosis Drug Production Value by Type (2018-2029)
5.3.3 World Primary Myelofibrosis Drug Average Price by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Primary Myelofibrosis Drug Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Adults
6.2.2 Children
6.3 Market Segment by Application
6.3.1 World Primary Myelofibrosis Drug Production by Application (2018-2029)
6.3.2 World Primary Myelofibrosis Drug Production Value by Application (2018-2029)
6.3.3 World Primary Myelofibrosis Drug Average Price by Application (2018-2029)
7 COMPANY PROFILES
7.1 GSK
7.1.1 GSK Details
7.1.2 GSK Major Business
7.1.3 GSK Primary Myelofibrosis Drug Product and Services
7.1.4 GSK Primary Myelofibrosis Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.1.5 GSK Recent Developments/Updates
7.1.6 GSK Competitive Strengths & Weaknesses
7.2 AbbVie
7.2.1 AbbVie Details
7.2.2 AbbVie Major Business
7.2.3 AbbVie Primary Myelofibrosis Drug Product and Services
7.2.4 AbbVie Primary Myelofibrosis Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.2.5 AbbVie Recent Developments/Updates
7.2.6 AbbVie Competitive Strengths & Weaknesses
7.3 Novartis
7.3.1 Novartis Details
7.3.2 Novartis Major Business
7.3.3 Novartis Primary Myelofibrosis Drug Product and Services
7.3.4 Novartis Primary Myelofibrosis Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.3.5 Novartis Recent Developments/Updates
7.3.6 Novartis Competitive Strengths & Weaknesses
7.4 Celgene
7.4.1 Celgene Details
7.4.2 Celgene Major Business
7.4.3 Celgene Primary Myelofibrosis Drug Product and Services
7.4.4 Celgene Primary Myelofibrosis Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.4.5 Celgene Recent Developments/Updates
7.4.6 Celgene Competitive Strengths & Weaknesses
7.5 Grunenthal
7.5.1 Grunenthal Details
7.5.2 Grunenthal Major Business
7.5.3 Grunenthal Primary Myelofibrosis Drug Product and Services
7.5.4 Grunenthal Primary Myelofibrosis Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.5.5 Grunenthal Recent Developments/Updates
7.5.6 Grunenthal Competitive Strengths & Weaknesses
7.6 Incyte
7.6.1 Incyte Details
7.6.2 Incyte Major Business
7.6.3 Incyte Primary Myelofibrosis Drug Product and Services
7.6.4 Incyte Primary Myelofibrosis Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.6.5 Incyte Recent Developments/Updates
7.6.6 Incyte Competitive Strengths & Weaknesses
7.7 CTI BioPharma
7.7.1 CTI BioPharma Details
7.7.2 CTI BioPharma Major Business
7.7.3 CTI BioPharma Primary Myelofibrosis Drug Product and Services
7.7.4 CTI BioPharma Primary Myelofibrosis Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.7.5 CTI BioPharma Recent Developments/Updates
7.7.6 CTI BioPharma Competitive Strengths & Weaknesses
7.8 Bristol Myers Squibb
7.8.1 Bristol Myers Squibb Details
7.8.2 Bristol Myers Squibb Major Business
7.8.3 Bristol Myers Squibb Primary Myelofibrosis Drug Product and Services
7.8.4 Bristol Myers Squibb Primary Myelofibrosis Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.8.5 Bristol Myers Squibb Recent Developments/Updates
7.8.6 Bristol Myers Squibb Competitive Strengths & Weaknesses
7.9 Suzhou Zelgen Biopharmaceuticals
7.9.1 Suzhou Zelgen Biopharmaceuticals Details
7.9.2 Suzhou Zelgen Biopharmaceuticals Major Business
7.9.3 Suzhou Zelgen Biopharmaceuticals Primary Myelofibrosis Drug Product and Services
7.9.4 Suzhou Zelgen Biopharmaceuticals Primary Myelofibrosis Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.9.5 Suzhou Zelgen Biopharmaceuticals Recent Developments/Updates
7.9.6 Suzhou Zelgen Biopharmaceuticals Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Primary Myelofibrosis Drug Industry Chain
8.2 Primary Myelofibrosis Drug Upstream Analysis
8.2.1 Primary Myelofibrosis Drug Core Raw Materials
8.2.2 Main Manufacturers of Primary Myelofibrosis Drug Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Primary Myelofibrosis Drug Production Mode
8.6 Primary Myelofibrosis Drug Procurement Model
8.7 Primary Myelofibrosis Drug Industry Sales Model and Sales Channels
8.7.1 Primary Myelofibrosis Drug Sales Model
8.7.2 Primary Myelofibrosis Drug Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Primary Myelofibrosis Drug Introduction
1.2 World Primary Myelofibrosis Drug Supply & Forecast
1.2.1 World Primary Myelofibrosis Drug Production Value (2018 & 2022 & 2029)
1.2.2 World Primary Myelofibrosis Drug Production (2018-2029)
1.2.3 World Primary Myelofibrosis Drug Pricing Trends (2018-2029)
1.3 World Primary Myelofibrosis Drug Production by Region (Based on Production Site)
1.3.1 World Primary Myelofibrosis Drug Production Value by Region (2018-2029)
1.3.2 World Primary Myelofibrosis Drug Production by Region (2018-2029)
1.3.3 World Primary Myelofibrosis Drug Average Price by Region (2018-2029)
1.3.4 North America Primary Myelofibrosis Drug Production (2018-2029)
1.3.5 Europe Primary Myelofibrosis Drug Production (2018-2029)
1.3.6 China Primary Myelofibrosis Drug Production (2018-2029)
1.3.7 Japan Primary Myelofibrosis Drug Production (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Primary Myelofibrosis Drug Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Primary Myelofibrosis Drug Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Primary Myelofibrosis Drug Demand (2018-2029)
2.2 World Primary Myelofibrosis Drug Consumption by Region
2.2.1 World Primary Myelofibrosis Drug Consumption by Region (2018-2023)
2.2.2 World Primary Myelofibrosis Drug Consumption Forecast by Region (2024-2029)
2.3 United States Primary Myelofibrosis Drug Consumption (2018-2029)
2.4 China Primary Myelofibrosis Drug Consumption (2018-2029)
2.5 Europe Primary Myelofibrosis Drug Consumption (2018-2029)
2.6 Japan Primary Myelofibrosis Drug Consumption (2018-2029)
2.7 South Korea Primary Myelofibrosis Drug Consumption (2018-2029)
2.8 ASEAN Primary Myelofibrosis Drug Consumption (2018-2029)
2.9 India Primary Myelofibrosis Drug Consumption (2018-2029)
3 WORLD PRIMARY MYELOFIBROSIS DRUG MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Primary Myelofibrosis Drug Production Value by Manufacturer (2018-2023)
3.2 World Primary Myelofibrosis Drug Production by Manufacturer (2018-2023)
3.3 World Primary Myelofibrosis Drug Average Price by Manufacturer (2018-2023)
3.4 Primary Myelofibrosis Drug Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Primary Myelofibrosis Drug Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Primary Myelofibrosis Drug in 2022
3.5.3 Global Concentration Ratios (CR8) for Primary Myelofibrosis Drug in 2022
3.6 Primary Myelofibrosis Drug Market: Overall Company Footprint Analysis
3.6.1 Primary Myelofibrosis Drug Market: Region Footprint
3.6.2 Primary Myelofibrosis Drug Market: Company Product Type Footprint
3.6.3 Primary Myelofibrosis Drug Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Primary Myelofibrosis Drug Production Value Comparison
4.1.1 United States VS China: Primary Myelofibrosis Drug Production Value Comparison (2018 & 2022 & 2029)
4.1.2 United States VS China: Primary Myelofibrosis Drug Production Value Market Share Comparison (2018 & 2022 & 2029)
4.2 United States VS China: Primary Myelofibrosis Drug Production Comparison
4.2.1 United States VS China: Primary Myelofibrosis Drug Production Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Primary Myelofibrosis Drug Production Market Share Comparison (2018 & 2022 & 2029)
4.3 United States VS China: Primary Myelofibrosis Drug Consumption Comparison
4.3.1 United States VS China: Primary Myelofibrosis Drug Consumption Comparison (2018 & 2022 & 2029)
4.3.2 United States VS China: Primary Myelofibrosis Drug Consumption Market Share Comparison (2018 & 2022 & 2029)
4.4 United States Based Primary Myelofibrosis Drug Manufacturers and Market Share, 2018-2023
4.4.1 United States Based Primary Myelofibrosis Drug Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Primary Myelofibrosis Drug Production Value (2018-2023)
4.4.3 United States Based Manufacturers Primary Myelofibrosis Drug Production (2018-2023)
4.5 China Based Primary Myelofibrosis Drug Manufacturers and Market Share
4.5.1 China Based Primary Myelofibrosis Drug Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Primary Myelofibrosis Drug Production Value (2018-2023)
4.5.3 China Based Manufacturers Primary Myelofibrosis Drug Production (2018-2023)
4.6 Rest of World Based Primary Myelofibrosis Drug Manufacturers and Market Share, 2018-2023
4.6.1 Rest of World Based Primary Myelofibrosis Drug Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Primary Myelofibrosis Drug Production Value (2018-2023)
4.6.3 Rest of World Based Manufacturers Primary Myelofibrosis Drug Production (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Primary Myelofibrosis Drug Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 JAK
5.2.2 JAK
5.2.3 Others
5.3 Market Segment by Type
5.3.1 World Primary Myelofibrosis Drug Production by Type (2018-2029)
5.3.2 World Primary Myelofibrosis Drug Production Value by Type (2018-2029)
5.3.3 World Primary Myelofibrosis Drug Average Price by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Primary Myelofibrosis Drug Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Adults
6.2.2 Children
6.3 Market Segment by Application
6.3.1 World Primary Myelofibrosis Drug Production by Application (2018-2029)
6.3.2 World Primary Myelofibrosis Drug Production Value by Application (2018-2029)
6.3.3 World Primary Myelofibrosis Drug Average Price by Application (2018-2029)
7 COMPANY PROFILES
7.1 GSK
7.1.1 GSK Details
7.1.2 GSK Major Business
7.1.3 GSK Primary Myelofibrosis Drug Product and Services
7.1.4 GSK Primary Myelofibrosis Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.1.5 GSK Recent Developments/Updates
7.1.6 GSK Competitive Strengths & Weaknesses
7.2 AbbVie
7.2.1 AbbVie Details
7.2.2 AbbVie Major Business
7.2.3 AbbVie Primary Myelofibrosis Drug Product and Services
7.2.4 AbbVie Primary Myelofibrosis Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.2.5 AbbVie Recent Developments/Updates
7.2.6 AbbVie Competitive Strengths & Weaknesses
7.3 Novartis
7.3.1 Novartis Details
7.3.2 Novartis Major Business
7.3.3 Novartis Primary Myelofibrosis Drug Product and Services
7.3.4 Novartis Primary Myelofibrosis Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.3.5 Novartis Recent Developments/Updates
7.3.6 Novartis Competitive Strengths & Weaknesses
7.4 Celgene
7.4.1 Celgene Details
7.4.2 Celgene Major Business
7.4.3 Celgene Primary Myelofibrosis Drug Product and Services
7.4.4 Celgene Primary Myelofibrosis Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.4.5 Celgene Recent Developments/Updates
7.4.6 Celgene Competitive Strengths & Weaknesses
7.5 Grunenthal
7.5.1 Grunenthal Details
7.5.2 Grunenthal Major Business
7.5.3 Grunenthal Primary Myelofibrosis Drug Product and Services
7.5.4 Grunenthal Primary Myelofibrosis Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.5.5 Grunenthal Recent Developments/Updates
7.5.6 Grunenthal Competitive Strengths & Weaknesses
7.6 Incyte
7.6.1 Incyte Details
7.6.2 Incyte Major Business
7.6.3 Incyte Primary Myelofibrosis Drug Product and Services
7.6.4 Incyte Primary Myelofibrosis Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.6.5 Incyte Recent Developments/Updates
7.6.6 Incyte Competitive Strengths & Weaknesses
7.7 CTI BioPharma
7.7.1 CTI BioPharma Details
7.7.2 CTI BioPharma Major Business
7.7.3 CTI BioPharma Primary Myelofibrosis Drug Product and Services
7.7.4 CTI BioPharma Primary Myelofibrosis Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.7.5 CTI BioPharma Recent Developments/Updates
7.7.6 CTI BioPharma Competitive Strengths & Weaknesses
7.8 Bristol Myers Squibb
7.8.1 Bristol Myers Squibb Details
7.8.2 Bristol Myers Squibb Major Business
7.8.3 Bristol Myers Squibb Primary Myelofibrosis Drug Product and Services
7.8.4 Bristol Myers Squibb Primary Myelofibrosis Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.8.5 Bristol Myers Squibb Recent Developments/Updates
7.8.6 Bristol Myers Squibb Competitive Strengths & Weaknesses
7.9 Suzhou Zelgen Biopharmaceuticals
7.9.1 Suzhou Zelgen Biopharmaceuticals Details
7.9.2 Suzhou Zelgen Biopharmaceuticals Major Business
7.9.3 Suzhou Zelgen Biopharmaceuticals Primary Myelofibrosis Drug Product and Services
7.9.4 Suzhou Zelgen Biopharmaceuticals Primary Myelofibrosis Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.9.5 Suzhou Zelgen Biopharmaceuticals Recent Developments/Updates
7.9.6 Suzhou Zelgen Biopharmaceuticals Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Primary Myelofibrosis Drug Industry Chain
8.2 Primary Myelofibrosis Drug Upstream Analysis
8.2.1 Primary Myelofibrosis Drug Core Raw Materials
8.2.2 Main Manufacturers of Primary Myelofibrosis Drug Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Primary Myelofibrosis Drug Production Mode
8.6 Primary Myelofibrosis Drug Procurement Model
8.7 Primary Myelofibrosis Drug Industry Sales Model and Sales Channels
8.7.1 Primary Myelofibrosis Drug Sales Model
8.7.2 Primary Myelofibrosis Drug Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Primary Myelofibrosis Drug Production Value by Region (2018, 2022 and 2029) & (USD Million)
Table 2. World Primary Myelofibrosis Drug Production Value by Region (2018-2023) & (USD Million)
Table 3. World Primary Myelofibrosis Drug Production Value by Region (2024-2029) & (USD Million)
Table 4. World Primary Myelofibrosis Drug Production Value Market Share by Region (2018-2023)
Table 5. World Primary Myelofibrosis Drug Production Value Market Share by Region (2024-2029)
Table 6. World Primary Myelofibrosis Drug Production by Region (2018-2023) & (K Units)
Table 7. World Primary Myelofibrosis Drug Production by Region (2024-2029) & (K Units)
Table 8. World Primary Myelofibrosis Drug Production Market Share by Region (2018-2023)
Table 9. World Primary Myelofibrosis Drug Production Market Share by Region (2024-2029)
Table 10. World Primary Myelofibrosis Drug Average Price by Region (2018-2023) & (US$/Unit)
Table 11. World Primary Myelofibrosis Drug Average Price by Region (2024-2029) & (US$/Unit)
Table 12. Primary Myelofibrosis Drug Major Market Trends
Table 13. World Primary Myelofibrosis Drug Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
Table 14. World Primary Myelofibrosis Drug Consumption by Region (2018-2023) & (K Units)
Table 15. World Primary Myelofibrosis Drug Consumption Forecast by Region (2024-2029) & (K Units)
Table 16. World Primary Myelofibrosis Drug Production Value by Manufacturer (2018-2023) & (USD Million)
Table 17. Production Value Market Share of Key Primary Myelofibrosis Drug Producers in 2022
Table 18. World Primary Myelofibrosis Drug Production by Manufacturer (2018-2023) & (K Units)
Table 19. Production Market Share of Key Primary Myelofibrosis Drug Producers in 2022
Table 20. World Primary Myelofibrosis Drug Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 21. Global Primary Myelofibrosis Drug Company Evaluation Quadrant
Table 22. World Primary Myelofibrosis Drug Industry Rank of Major Manufacturers, Based on Production Value in 2022
Table 23. Head Office and Primary Myelofibrosis Drug Production Site of Key Manufacturer
Table 24. Primary Myelofibrosis Drug Market: Company Product Type Footprint
Table 25. Primary Myelofibrosis Drug Market: Company Product Application Footprint
Table 26. Primary Myelofibrosis Drug Competitive Factors
Table 27. Primary Myelofibrosis Drug New Entrant and Capacity Expansion Plans
Table 28. Primary Myelofibrosis Drug Mergers & Acquisitions Activity
Table 29. United States VS China Primary Myelofibrosis Drug Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 30. United States VS China Primary Myelofibrosis Drug Production Comparison, (2018 & 2022 & 2029) & (K Units)
Table 31. United States VS China Primary Myelofibrosis Drug Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
Table 32. United States Based Primary Myelofibrosis Drug Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Primary Myelofibrosis Drug Production Value, (2018-2023) & (USD Million)
Table 34. United States Based Manufacturers Primary Myelofibrosis Drug Production Value Market Share (2018-2023)
Table 35. United States Based Manufacturers Primary Myelofibrosis Drug Production (2018-2023) & (K Units)
Table 36. United States Based Manufacturers Primary Myelofibrosis Drug Production Market Share (2018-2023)
Table 37. China Based Primary Myelofibrosis Drug Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Primary Myelofibrosis Drug Production Value, (2018-2023) & (USD Million)
Table 39. China Based Manufacturers Primary Myelofibrosis Drug Production Value Market Share (2018-2023)
Table 40. China Based Manufacturers Primary Myelofibrosis Drug Production (2018-2023) & (K Units)
Table 41. China Based Manufacturers Primary Myelofibrosis Drug Production Market Share (2018-2023)
Table 42. Rest of World Based Primary Myelofibrosis Drug Manufacturers, Headquarters and Production Site (States, Country)
Table 43. Rest of World Based Manufacturers Primary Myelofibrosis Drug Production Value, (2018-2023) & (USD Million)
Table 44. Rest of World Based Manufacturers Primary Myelofibrosis Drug Production Value Market Share (2018-2023)
Table 45. Rest of World Based Manufacturers Primary Myelofibrosis Drug Production (2018-2023) & (K Units)
Table 46. Rest of World Based Manufacturers Primary Myelofibrosis Drug Production Market Share (2018-2023)
Table 47. World Primary Myelofibrosis Drug Production Value by Type, (USD Million), 2018 & 2022 & 2029
Table 48. World Primary Myelofibrosis Drug Production by Type (2018-2023) & (K Units)
Table 49. World Primary Myelofibrosis Drug Production by Type (2024-2029) & (K Units)
Table 50. World Primary Myelofibrosis Drug Production Value by Type (2018-2023) & (USD Million)
Table 51. World Primary Myelofibrosis Drug Production Value by Type (2024-2029) & (USD Million)
Table 52. World Primary Myelofibrosis Drug Average Price by Type (2018-2023) & (US$/Unit)
Table 53. World Primary Myelofibrosis Drug Average Price by Type (2024-2029) & (US$/Unit)
Table 54. World Primary Myelofibrosis Drug Production Value by Application, (USD Million), 2018 & 2022 & 2029
Table 55. World Primary Myelofibrosis Drug Production by Application (2018-2023) & (K Units)
Table 56. World Primary Myelofibrosis Drug Production by Application (2024-2029) & (K Units)
Table 57. World Primary Myelofibrosis Drug Production Value by Application (2018-2023) & (USD Million)
Table 58. World Primary Myelofibrosis Drug Production Value by Application (2024-2029) & (USD Million)
Table 59. World Primary Myelofibrosis Drug Average Price by Application (2018-2023) & (US$/Unit)
Table 60. World Primary Myelofibrosis Drug Average Price by Application (2024-2029) & (US$/Unit)
Table 61. GSK Basic Information, Manufacturing Base and Competitors
Table 62. GSK Major Business
Table 63. GSK Primary Myelofibrosis Drug Product and Services
Table 64. GSK Primary Myelofibrosis Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 65. GSK Recent Developments/Updates
Table 66. GSK Competitive Strengths & Weaknesses
Table 67. AbbVie Basic Information, Manufacturing Base and Competitors
Table 68. AbbVie Major Business
Table 69. AbbVie Primary Myelofibrosis Drug Product and Services
Table 70. AbbVie Primary Myelofibrosis Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 71. AbbVie Recent Developments/Updates
Table 72. AbbVie Competitive Strengths & Weaknesses
Table 73. Novartis Basic Information, Manufacturing Base and Competitors
Table 74. Novartis Major Business
Table 75. Novartis Primary Myelofibrosis Drug Product and Services
Table 76. Novartis Primary Myelofibrosis Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Novartis Recent Developments/Updates
Table 78. Novartis Competitive Strengths & Weaknesses
Table 79. Celgene Basic Information, Manufacturing Base and Competitors
Table 80. Celgene Major Business
Table 81. Celgene Primary Myelofibrosis Drug Product and Services
Table 82. Celgene Primary Myelofibrosis Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 83. Celgene Recent Developments/Updates
Table 84. Celgene Competitive Strengths & Weaknesses
Table 85. Grunenthal Basic Information, Manufacturing Base and Competitors
Table 86. Grunenthal Major Business
Table 87. Grunenthal Primary Myelofibrosis Drug Product and Services
Table 88. Grunenthal Primary Myelofibrosis Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. Grunenthal Recent Developments/Updates
Table 90. Grunenthal Competitive Strengths & Weaknesses
Table 91. Incyte Basic Information, Manufacturing Base and Competitors
Table 92. Incyte Major Business
Table 93. Incyte Primary Myelofibrosis Drug Product and Services
Table 94. Incyte Primary Myelofibrosis Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 95. Incyte Recent Developments/Updates
Table 96. Incyte Competitive Strengths & Weaknesses
Table 97. CTI BioPharma Basic Information, Manufacturing Base and Competitors
Table 98. CTI BioPharma Major Business
Table 99. CTI BioPharma Primary Myelofibrosis Drug Product and Services
Table 100. CTI BioPharma Primary Myelofibrosis Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 101. CTI BioPharma Recent Developments/Updates
Table 102. CTI BioPharma Competitive Strengths & Weaknesses
Table 103. Bristol Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 104. Bristol Myers Squibb Major Business
Table 105. Bristol Myers Squibb Primary Myelofibrosis Drug Product and Services
Table 106. Bristol Myers Squibb Primary Myelofibrosis Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 107. Bristol Myers Squibb Recent Developments/Updates
Table 108. Suzhou Zelgen Biopharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 109. Suzhou Zelgen Biopharmaceuticals Major Business
Table 110. Suzhou Zelgen Biopharmaceuticals Primary Myelofibrosis Drug Product and Services
Table 111. Suzhou Zelgen Biopharmaceuticals Primary Myelofibrosis Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 112. Global Key Players of Primary Myelofibrosis Drug Upstream (Raw Materials)
Table 113. Primary Myelofibrosis Drug Typical Customers
Table 114. Primary Myelofibrosis Drug Typical Distributors
Table 1. World Primary Myelofibrosis Drug Production Value by Region (2018, 2022 and 2029) & (USD Million)
Table 2. World Primary Myelofibrosis Drug Production Value by Region (2018-2023) & (USD Million)
Table 3. World Primary Myelofibrosis Drug Production Value by Region (2024-2029) & (USD Million)
Table 4. World Primary Myelofibrosis Drug Production Value Market Share by Region (2018-2023)
Table 5. World Primary Myelofibrosis Drug Production Value Market Share by Region (2024-2029)
Table 6. World Primary Myelofibrosis Drug Production by Region (2018-2023) & (K Units)
Table 7. World Primary Myelofibrosis Drug Production by Region (2024-2029) & (K Units)
Table 8. World Primary Myelofibrosis Drug Production Market Share by Region (2018-2023)
Table 9. World Primary Myelofibrosis Drug Production Market Share by Region (2024-2029)
Table 10. World Primary Myelofibrosis Drug Average Price by Region (2018-2023) & (US$/Unit)
Table 11. World Primary Myelofibrosis Drug Average Price by Region (2024-2029) & (US$/Unit)
Table 12. Primary Myelofibrosis Drug Major Market Trends
Table 13. World Primary Myelofibrosis Drug Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
Table 14. World Primary Myelofibrosis Drug Consumption by Region (2018-2023) & (K Units)
Table 15. World Primary Myelofibrosis Drug Consumption Forecast by Region (2024-2029) & (K Units)
Table 16. World Primary Myelofibrosis Drug Production Value by Manufacturer (2018-2023) & (USD Million)
Table 17. Production Value Market Share of Key Primary Myelofibrosis Drug Producers in 2022
Table 18. World Primary Myelofibrosis Drug Production by Manufacturer (2018-2023) & (K Units)
Table 19. Production Market Share of Key Primary Myelofibrosis Drug Producers in 2022
Table 20. World Primary Myelofibrosis Drug Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 21. Global Primary Myelofibrosis Drug Company Evaluation Quadrant
Table 22. World Primary Myelofibrosis Drug Industry Rank of Major Manufacturers, Based on Production Value in 2022
Table 23. Head Office and Primary Myelofibrosis Drug Production Site of Key Manufacturer
Table 24. Primary Myelofibrosis Drug Market: Company Product Type Footprint
Table 25. Primary Myelofibrosis Drug Market: Company Product Application Footprint
Table 26. Primary Myelofibrosis Drug Competitive Factors
Table 27. Primary Myelofibrosis Drug New Entrant and Capacity Expansion Plans
Table 28. Primary Myelofibrosis Drug Mergers & Acquisitions Activity
Table 29. United States VS China Primary Myelofibrosis Drug Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 30. United States VS China Primary Myelofibrosis Drug Production Comparison, (2018 & 2022 & 2029) & (K Units)
Table 31. United States VS China Primary Myelofibrosis Drug Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
Table 32. United States Based Primary Myelofibrosis Drug Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Primary Myelofibrosis Drug Production Value, (2018-2023) & (USD Million)
Table 34. United States Based Manufacturers Primary Myelofibrosis Drug Production Value Market Share (2018-2023)
Table 35. United States Based Manufacturers Primary Myelofibrosis Drug Production (2018-2023) & (K Units)
Table 36. United States Based Manufacturers Primary Myelofibrosis Drug Production Market Share (2018-2023)
Table 37. China Based Primary Myelofibrosis Drug Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Primary Myelofibrosis Drug Production Value, (2018-2023) & (USD Million)
Table 39. China Based Manufacturers Primary Myelofibrosis Drug Production Value Market Share (2018-2023)
Table 40. China Based Manufacturers Primary Myelofibrosis Drug Production (2018-2023) & (K Units)
Table 41. China Based Manufacturers Primary Myelofibrosis Drug Production Market Share (2018-2023)
Table 42. Rest of World Based Primary Myelofibrosis Drug Manufacturers, Headquarters and Production Site (States, Country)
Table 43. Rest of World Based Manufacturers Primary Myelofibrosis Drug Production Value, (2018-2023) & (USD Million)
Table 44. Rest of World Based Manufacturers Primary Myelofibrosis Drug Production Value Market Share (2018-2023)
Table 45. Rest of World Based Manufacturers Primary Myelofibrosis Drug Production (2018-2023) & (K Units)
Table 46. Rest of World Based Manufacturers Primary Myelofibrosis Drug Production Market Share (2018-2023)
Table 47. World Primary Myelofibrosis Drug Production Value by Type, (USD Million), 2018 & 2022 & 2029
Table 48. World Primary Myelofibrosis Drug Production by Type (2018-2023) & (K Units)
Table 49. World Primary Myelofibrosis Drug Production by Type (2024-2029) & (K Units)
Table 50. World Primary Myelofibrosis Drug Production Value by Type (2018-2023) & (USD Million)
Table 51. World Primary Myelofibrosis Drug Production Value by Type (2024-2029) & (USD Million)
Table 52. World Primary Myelofibrosis Drug Average Price by Type (2018-2023) & (US$/Unit)
Table 53. World Primary Myelofibrosis Drug Average Price by Type (2024-2029) & (US$/Unit)
Table 54. World Primary Myelofibrosis Drug Production Value by Application, (USD Million), 2018 & 2022 & 2029
Table 55. World Primary Myelofibrosis Drug Production by Application (2018-2023) & (K Units)
Table 56. World Primary Myelofibrosis Drug Production by Application (2024-2029) & (K Units)
Table 57. World Primary Myelofibrosis Drug Production Value by Application (2018-2023) & (USD Million)
Table 58. World Primary Myelofibrosis Drug Production Value by Application (2024-2029) & (USD Million)
Table 59. World Primary Myelofibrosis Drug Average Price by Application (2018-2023) & (US$/Unit)
Table 60. World Primary Myelofibrosis Drug Average Price by Application (2024-2029) & (US$/Unit)
Table 61. GSK Basic Information, Manufacturing Base and Competitors
Table 62. GSK Major Business
Table 63. GSK Primary Myelofibrosis Drug Product and Services
Table 64. GSK Primary Myelofibrosis Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 65. GSK Recent Developments/Updates
Table 66. GSK Competitive Strengths & Weaknesses
Table 67. AbbVie Basic Information, Manufacturing Base and Competitors
Table 68. AbbVie Major Business
Table 69. AbbVie Primary Myelofibrosis Drug Product and Services
Table 70. AbbVie Primary Myelofibrosis Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 71. AbbVie Recent Developments/Updates
Table 72. AbbVie Competitive Strengths & Weaknesses
Table 73. Novartis Basic Information, Manufacturing Base and Competitors
Table 74. Novartis Major Business
Table 75. Novartis Primary Myelofibrosis Drug Product and Services
Table 76. Novartis Primary Myelofibrosis Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Novartis Recent Developments/Updates
Table 78. Novartis Competitive Strengths & Weaknesses
Table 79. Celgene Basic Information, Manufacturing Base and Competitors
Table 80. Celgene Major Business
Table 81. Celgene Primary Myelofibrosis Drug Product and Services
Table 82. Celgene Primary Myelofibrosis Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 83. Celgene Recent Developments/Updates
Table 84. Celgene Competitive Strengths & Weaknesses
Table 85. Grunenthal Basic Information, Manufacturing Base and Competitors
Table 86. Grunenthal Major Business
Table 87. Grunenthal Primary Myelofibrosis Drug Product and Services
Table 88. Grunenthal Primary Myelofibrosis Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. Grunenthal Recent Developments/Updates
Table 90. Grunenthal Competitive Strengths & Weaknesses
Table 91. Incyte Basic Information, Manufacturing Base and Competitors
Table 92. Incyte Major Business
Table 93. Incyte Primary Myelofibrosis Drug Product and Services
Table 94. Incyte Primary Myelofibrosis Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 95. Incyte Recent Developments/Updates
Table 96. Incyte Competitive Strengths & Weaknesses
Table 97. CTI BioPharma Basic Information, Manufacturing Base and Competitors
Table 98. CTI BioPharma Major Business
Table 99. CTI BioPharma Primary Myelofibrosis Drug Product and Services
Table 100. CTI BioPharma Primary Myelofibrosis Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 101. CTI BioPharma Recent Developments/Updates
Table 102. CTI BioPharma Competitive Strengths & Weaknesses
Table 103. Bristol Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 104. Bristol Myers Squibb Major Business
Table 105. Bristol Myers Squibb Primary Myelofibrosis Drug Product and Services
Table 106. Bristol Myers Squibb Primary Myelofibrosis Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 107. Bristol Myers Squibb Recent Developments/Updates
Table 108. Suzhou Zelgen Biopharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 109. Suzhou Zelgen Biopharmaceuticals Major Business
Table 110. Suzhou Zelgen Biopharmaceuticals Primary Myelofibrosis Drug Product and Services
Table 111. Suzhou Zelgen Biopharmaceuticals Primary Myelofibrosis Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 112. Global Key Players of Primary Myelofibrosis Drug Upstream (Raw Materials)
Table 113. Primary Myelofibrosis Drug Typical Customers
Table 114. Primary Myelofibrosis Drug Typical Distributors
LIST OF FIGURES
Figure 1. Primary Myelofibrosis Drug Picture
Figure 2. World Primary Myelofibrosis Drug Production Value: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Primary Myelofibrosis Drug Production Value and Forecast (2018-2029) & (USD Million)
Figure 4. World Primary Myelofibrosis Drug Production (2018-2029) & (K Units)
Figure 5. World Primary Myelofibrosis Drug Average Price (2018-2029) & (US$/Unit)
Figure 6. World Primary Myelofibrosis Drug Production Value Market Share by Region (2018-2029)
Figure 7. World Primary Myelofibrosis Drug Production Market Share by Region (2018-2029)
Figure 8. North America Primary Myelofibrosis Drug Production (2018-2029) & (K Units)
Figure 9. Europe Primary Myelofibrosis Drug Production (2018-2029) & (K Units)
Figure 10. China Primary Myelofibrosis Drug Production (2018-2029) & (K Units)
Figure 11. Japan Primary Myelofibrosis Drug Production (2018-2029) & (K Units)
Figure 12. Primary Myelofibrosis Drug Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Primary Myelofibrosis Drug Consumption (2018-2029) & (K Units)
Figure 15. World Primary Myelofibrosis Drug Consumption Market Share by Region (2018-2029)
Figure 16. United States Primary Myelofibrosis Drug Consumption (2018-2029) & (K Units)
Figure 17. China Primary Myelofibrosis Drug Consumption (2018-2029) & (K Units)
Figure 18. Europe Primary Myelofibrosis Drug Consumption (2018-2029) & (K Units)
Figure 19. Japan Primary Myelofibrosis Drug Consumption (2018-2029) & (K Units)
Figure 20. South Korea Primary Myelofibrosis Drug Consumption (2018-2029) & (K Units)
Figure 21. ASEAN Primary Myelofibrosis Drug Consumption (2018-2029) & (K Units)
Figure 22. India Primary Myelofibrosis Drug Consumption (2018-2029) & (K Units)
Figure 23. Producer Shipments of Primary Myelofibrosis Drug by Manufacturer Revenue ($MM) and Market Share (%): 2022
Figure 24. Global Four-firm Concentration Ratios (CR4) for Primary Myelofibrosis Drug Markets in 2022
Figure 25. Global Four-firm Concentration Ratios (CR8) for Primary Myelofibrosis Drug Markets in 2022
Figure 26. United States VS China: Primary Myelofibrosis Drug Production Value Market Share Comparison (2018 & 2022 & 2029)
Figure 27. United States VS China: Primary Myelofibrosis Drug Production Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Primary Myelofibrosis Drug Consumption Market Share Comparison (2018 & 2022 & 2029)
Figure 29. United States Based Manufacturers Primary Myelofibrosis Drug Production Market Share 2022
Figure 30. China Based Manufacturers Primary Myelofibrosis Drug Production Market Share 2022
Figure 31. Rest of World Based Manufacturers Primary Myelofibrosis Drug Production Market Share 2022
Figure 32. World Primary Myelofibrosis Drug Production Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 33. World Primary Myelofibrosis Drug Production Value Market Share by Type in 2022
Figure 34. JAK 1
Figure 35. JAK 2
Figure 36. Others
Figure 37. World Primary Myelofibrosis Drug Production Market Share by Type (2018-2029)
Figure 38. World Primary Myelofibrosis Drug Production Value Market Share by Type (2018-2029)
Figure 39. World Primary Myelofibrosis Drug Average Price by Type (2018-2029) & (US$/Unit)
Figure 40. World Primary Myelofibrosis Drug Production Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 41. World Primary Myelofibrosis Drug Production Value Market Share by Application in 2022
Figure 42. Adults
Figure 43. Children
Figure 44. World Primary Myelofibrosis Drug Production Market Share by Application (2018-2029)
Figure 45. World Primary Myelofibrosis Drug Production Value Market Share by Application (2018-2029)
Figure 46. World Primary Myelofibrosis Drug Average Price by Application (2018-2029) & (US$/Unit)
Figure 47. Primary Myelofibrosis Drug Industry Chain
Figure 48. Primary Myelofibrosis Drug Procurement Model
Figure 49. Primary Myelofibrosis Drug Sales Model
Figure 50. Primary Myelofibrosis Drug Sales Channels, Direct Sales, and Distribution
Figure 51. Methodology
Figure 52. Research Process and Data Source
Figure 1. Primary Myelofibrosis Drug Picture
Figure 2. World Primary Myelofibrosis Drug Production Value: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Primary Myelofibrosis Drug Production Value and Forecast (2018-2029) & (USD Million)
Figure 4. World Primary Myelofibrosis Drug Production (2018-2029) & (K Units)
Figure 5. World Primary Myelofibrosis Drug Average Price (2018-2029) & (US$/Unit)
Figure 6. World Primary Myelofibrosis Drug Production Value Market Share by Region (2018-2029)
Figure 7. World Primary Myelofibrosis Drug Production Market Share by Region (2018-2029)
Figure 8. North America Primary Myelofibrosis Drug Production (2018-2029) & (K Units)
Figure 9. Europe Primary Myelofibrosis Drug Production (2018-2029) & (K Units)
Figure 10. China Primary Myelofibrosis Drug Production (2018-2029) & (K Units)
Figure 11. Japan Primary Myelofibrosis Drug Production (2018-2029) & (K Units)
Figure 12. Primary Myelofibrosis Drug Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Primary Myelofibrosis Drug Consumption (2018-2029) & (K Units)
Figure 15. World Primary Myelofibrosis Drug Consumption Market Share by Region (2018-2029)
Figure 16. United States Primary Myelofibrosis Drug Consumption (2018-2029) & (K Units)
Figure 17. China Primary Myelofibrosis Drug Consumption (2018-2029) & (K Units)
Figure 18. Europe Primary Myelofibrosis Drug Consumption (2018-2029) & (K Units)
Figure 19. Japan Primary Myelofibrosis Drug Consumption (2018-2029) & (K Units)
Figure 20. South Korea Primary Myelofibrosis Drug Consumption (2018-2029) & (K Units)
Figure 21. ASEAN Primary Myelofibrosis Drug Consumption (2018-2029) & (K Units)
Figure 22. India Primary Myelofibrosis Drug Consumption (2018-2029) & (K Units)
Figure 23. Producer Shipments of Primary Myelofibrosis Drug by Manufacturer Revenue ($MM) and Market Share (%): 2022
Figure 24. Global Four-firm Concentration Ratios (CR4) for Primary Myelofibrosis Drug Markets in 2022
Figure 25. Global Four-firm Concentration Ratios (CR8) for Primary Myelofibrosis Drug Markets in 2022
Figure 26. United States VS China: Primary Myelofibrosis Drug Production Value Market Share Comparison (2018 & 2022 & 2029)
Figure 27. United States VS China: Primary Myelofibrosis Drug Production Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Primary Myelofibrosis Drug Consumption Market Share Comparison (2018 & 2022 & 2029)
Figure 29. United States Based Manufacturers Primary Myelofibrosis Drug Production Market Share 2022
Figure 30. China Based Manufacturers Primary Myelofibrosis Drug Production Market Share 2022
Figure 31. Rest of World Based Manufacturers Primary Myelofibrosis Drug Production Market Share 2022
Figure 32. World Primary Myelofibrosis Drug Production Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 33. World Primary Myelofibrosis Drug Production Value Market Share by Type in 2022
Figure 34. JAK 1
Figure 35. JAK 2
Figure 36. Others
Figure 37. World Primary Myelofibrosis Drug Production Market Share by Type (2018-2029)
Figure 38. World Primary Myelofibrosis Drug Production Value Market Share by Type (2018-2029)
Figure 39. World Primary Myelofibrosis Drug Average Price by Type (2018-2029) & (US$/Unit)
Figure 40. World Primary Myelofibrosis Drug Production Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 41. World Primary Myelofibrosis Drug Production Value Market Share by Application in 2022
Figure 42. Adults
Figure 43. Children
Figure 44. World Primary Myelofibrosis Drug Production Market Share by Application (2018-2029)
Figure 45. World Primary Myelofibrosis Drug Production Value Market Share by Application (2018-2029)
Figure 46. World Primary Myelofibrosis Drug Average Price by Application (2018-2029) & (US$/Unit)
Figure 47. Primary Myelofibrosis Drug Industry Chain
Figure 48. Primary Myelofibrosis Drug Procurement Model
Figure 49. Primary Myelofibrosis Drug Sales Model
Figure 50. Primary Myelofibrosis Drug Sales Channels, Direct Sales, and Distribution
Figure 51. Methodology
Figure 52. Research Process and Data Source
